All In Biotech

Drug Trial Radar · NCT06033586

Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera

An Extension Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera (THRIVE)

Last checked: Nov 20, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

46

Actual

Start

Jan 22, 2024

Primary completion

Apr 1, 2026

Study completion Apr 1, 2027

Sponsor

Lead sponsor
Protagonist Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess long-term safety and efficacy of rusfertide in subjects with polycythemia vera. Subjects who complete dosing with rusfertide until the end-of-treatment visit of a Phase 2 rusfertide study and meet the inclusion/exclusion criteria for this study, are eligible to participate in this open-label study and continue treatment with rusfertide.

Conditions

  • Polycythemia Vera

Interventions

  • Open-label rusfertideDrug

    subcutaneous rusfertide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HematocritTime frame: 0-2 years
  2. PhlebotomiesTime frame: 0-2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pontchartrain Cancer Care

    Covington, Louisiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.